Analysis of factors influencing the efficacy of NAC and prognosis between HER2-zero and HER2-low HR negative breast cancer

医学 乳腺癌 内科学 三阴性乳腺癌 病态的 分级(工程) 肿瘤科 曲妥珠单抗 人表皮生长因子受体2 化疗 激素受体 HER2阴性 癌症 胃肠病学 转移性乳腺癌 土木工程 工程类
作者
Jingjing Liu,Yi Zhang,Shichao Zhang,Xu Liu,Shunan Wang,Xinyu Liu,Jin Zhang
出处
期刊:Frontiers in Cell and Developmental Biology [Frontiers Media SA]
卷期号:12
标识
DOI:10.3389/fcell.2024.1417271
摘要

Objective: The aim of this paper was to assess the differences in clinicopathological characteristics, efficacy and prognosis of neoadjuvant chemotherapy (NAC) in human epidermal growth factor receptor2(HER2)-zero and HER2-low hormone receptor (HR)-negative breast cancer (BC) patients, and the impact of HER2-evolution on prognosis before and after NAC. Methods: 319 triple negative breast cancer (TNBC) patients who completed NAC and surgery from August 2014 to August 2018 at Tianjin Medical University Cancer Institute and Hospital were included. Clinicopathological features, efficacy of NAC and assessment of prognosis were retrospectively analysed. The evolution of HER2-zero to HER2-low after NAC is defined as HER2-gain, the evolution of HER2-low to HER2-zero after NAC is defined as HER2-loss, and HER2 unchanged after NAC is defined as HER2-stable. Results: In HR-negative BC, the pathological complete response (pCR) rate was significantly higher in HER2-zero compared with HER2-low patients, and the difference was statistically significant (38.9% vs 23.2%, p = 0.004), but there was no significant difference in the prognosis between the two groups. The overall rate of HER2-evolution after NAC was 19.7%, and there was a significant correlation between HER2-loss and histological grading, whereas HER2-gain was significantly associated with Ki-67 expression. In terms of prognosis, HER2-gain was better compared to the other two groups. Conclusion: In this study, we found that HER2-low HR-negative BC showed different clinicopathological features and response to NAC compared with HER2-zero, as well as HER2-evolution before and after NAC had a significant impact on prognosis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
YAN完成签到,获得积分10
刚刚
胡明月发布了新的文献求助10
1秒前
阿嘎普莱特完成签到,获得积分10
1秒前
赘婿应助WilliamYen采纳,获得10
2秒前
jinshiyu58发布了新的文献求助10
4秒前
脑洞疼应助沈业桥采纳,获得10
6秒前
6秒前
汉堡包应助胡明月采纳,获得10
7秒前
9秒前
科研通AI2S应助guojingjing采纳,获得10
11秒前
13秒前
13秒前
科研通AI2S应助OMR123采纳,获得10
14秒前
14秒前
萧水白应助罗小黑采纳,获得10
14秒前
14秒前
14秒前
胡明月完成签到,获得积分10
15秒前
15秒前
领导范儿应助lilili采纳,获得30
15秒前
16秒前
56发布了新的文献求助10
17秒前
ding应助淡然又菡采纳,获得30
18秒前
科研小迷糊完成签到,获得积分10
18秒前
谨慎惋庭发布了新的文献求助10
19秒前
21秒前
学术暴君发布了新的文献求助10
22秒前
小程同学发布了新的文献求助10
22秒前
水水完成签到,获得积分10
24秒前
隐形的蓝天完成签到,获得积分10
24秒前
24秒前
复杂函完成签到,获得积分10
25秒前
天真豪发布了新的文献求助10
26秒前
乐乐乐乐乐乐应助月12采纳,获得10
27秒前
共享精神应助kaiserkkk采纳,获得10
28秒前
lllzz发布了新的文献求助10
29秒前
Lucia发布了新的文献求助10
29秒前
cocolu应助orchid采纳,获得10
33秒前
xjz240221完成签到 ,获得积分10
33秒前
月12完成签到,获得积分20
34秒前
高分求助中
Solution Manual for Strategic Compensation A Human Resource Management Approach 1200
Natural History of Mantodea 螳螂的自然史 1000
Glucuronolactone Market Outlook Report: Industry Size, Competition, Trends and Growth Opportunities by Region, YoY Forecasts from 2024 to 2031 800
A Photographic Guide to Mantis of China 常见螳螂野外识别手册 800
Zeitschrift für Orient-Archäologie 500
Smith-Purcell Radiation 500
Autoregulatory progressive resistance exercise: linear versus a velocity-based flexible model 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 细胞生物学 免疫学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3343625
求助须知:如何正确求助?哪些是违规求助? 2970630
关于积分的说明 8644716
捐赠科研通 2650766
什么是DOI,文献DOI怎么找? 1451444
科研通“疑难数据库(出版商)”最低求助积分说明 672137
邀请新用户注册赠送积分活动 661569